NZ580162A - Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor - Google Patents
Combination anticoagulant therapy with a compound that acts as a factor xa inhibitorInfo
- Publication number
- NZ580162A NZ580162A NZ580162A NZ58016208A NZ580162A NZ 580162 A NZ580162 A NZ 580162A NZ 580162 A NZ580162 A NZ 580162A NZ 58016208 A NZ58016208 A NZ 58016208A NZ 580162 A NZ580162 A NZ 580162A
- Authority
- NZ
- New Zealand
- Prior art keywords
- agent
- compound
- receptor antagonist
- inhibitor
- acts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003146 anticoagulant agent Substances 0.000 title abstract 2
- 229940127219 anticoagulant drug Drugs 0.000 title abstract 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 239000002464 receptor antagonist Substances 0.000 abstract 3
- 229940044551 receptor antagonist Drugs 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 abstract 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 abstract 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 abstract 1
- 229940122388 Thrombin inhibitor Drugs 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 229940127218 antiplatelet drug Drugs 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 229960001080 cangrelor Drugs 0.000 abstract 1
- PAEBIVWUMLRPSK-IDTAVKCVSA-N cangrelor Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O PAEBIVWUMLRPSK-IDTAVKCVSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229960003009 clopidogrel Drugs 0.000 abstract 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- PGOYJYHMBCZDLN-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-2-[[4-[(dimethylhydrazinylidene)methyl]benzoyl]amino]-5-methoxybenzamide Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C=NN(C)C)C=C1 PGOYJYHMBCZDLN-UHFFFAOYSA-N 0.000 abstract 1
- 229960004197 prasugrel Drugs 0.000 abstract 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000003868 thrombin inhibitor Substances 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
- 229960002528 ticagrelor Drugs 0.000 abstract 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 abstract 1
- 229960005001 ticlopidine Drugs 0.000 abstract 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91185207P | 2007-04-13 | 2007-04-13 | |
| PCT/US2008/004760 WO2008127682A2 (en) | 2007-04-13 | 2008-04-11 | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ580162A true NZ580162A (en) | 2012-10-26 |
Family
ID=39638994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ580162A NZ580162A (en) | 2007-04-13 | 2008-04-11 | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20080254036A1 (enExample) |
| EP (2) | EP2155195B1 (enExample) |
| JP (2) | JP5469595B2 (enExample) |
| KR (1) | KR101473207B1 (enExample) |
| CN (2) | CN101743001B (enExample) |
| AU (1) | AU2008239659B2 (enExample) |
| BR (1) | BRPI0809655B8 (enExample) |
| CA (1) | CA2683793C (enExample) |
| DO (1) | DOP2009000244A (enExample) |
| EA (1) | EA020531B1 (enExample) |
| GT (1) | GT200900260A (enExample) |
| IL (1) | IL201433A (enExample) |
| MX (1) | MX2009010953A (enExample) |
| NZ (1) | NZ580162A (enExample) |
| TN (1) | TN2009000408A1 (enExample) |
| WO (1) | WO2008127682A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2254385T3 (es) | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| JP5020073B2 (ja) | 2004-06-18 | 2012-09-05 | ミレニアム ファーマシューティカルズ インク． | 第Ｘａ因子阻害剤 |
| US20090186810A1 (en) * | 2006-03-27 | 2009-07-23 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
| EA015942B1 (ru) * | 2006-05-05 | 2011-12-30 | Милленниум Фамэсьютикэлс, Инк. | Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови |
| PT2077995E (pt) * | 2006-11-02 | 2012-05-10 | Millennium Pharm Inc | Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa |
| EP2114930A2 (en) * | 2007-01-05 | 2009-11-11 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| NZ599556A (en) * | 2007-05-02 | 2013-10-25 | Portola Pharm Inc | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| BR112012011298B1 (pt) * | 2009-11-11 | 2021-12-14 | Chiesi Farmaceutici S.P.A. | Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos |
| WO2011075602A1 (en) | 2009-12-17 | 2011-06-23 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
| US8394964B2 (en) | 2009-12-17 | 2013-03-12 | Millennium Pharmaceuticals, Inc. | Methods of synthesizing factor Xa inhibitors |
| WO2011084652A2 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Salts and crystalline forms of a factor xa inhibitor |
| ES2548845T3 (es) * | 2009-12-23 | 2015-10-21 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico |
| US20120052058A1 (en) * | 2010-08-30 | 2012-03-01 | Emory University | Methods of managing the blood coagulation and pharmaceutical compositions related thereto |
| TW201221128A (en) | 2010-09-01 | 2012-06-01 | Portola Pharm Inc | Crystalline forms of a factor Xa inhibitor |
| AR082803A1 (es) * | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p |
| US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| US10603316B2 (en) | 2013-08-21 | 2020-03-31 | Morehouse School Of Medicine | Composition and methods for preventing or reducing the incidence of transient ischemic attacks |
| US10471163B2 (en) | 2013-09-13 | 2019-11-12 | The General Hospital Corporation | Activatable fibrin-binding probes |
| TW201613581A (en) * | 2014-09-02 | 2016-04-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition for suppression of thromboembolization after stent placement |
| WO2017091757A1 (en) | 2015-11-24 | 2017-06-01 | Portola Pharmaceuticals, Inc. | Isotopically enriched betrixaban |
| EP3463352A4 (en) * | 2016-06-02 | 2019-10-30 | Dr. Reddy S Laboratories Limited | POLYMORPH OF BETRIXABAN AND ITS MALEATE SALT |
| WO2018234565A1 (en) | 2017-06-23 | 2018-12-27 | Chiesi Farmaceutici S.P.A. | METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY |
| CN112888312A (zh) * | 2018-08-28 | 2021-06-01 | 莫尔豪斯医学院 | 用于预防或降低短暂性脑缺血发作发病率的组合物及方法 |
| CN116782911A (zh) * | 2020-09-17 | 2023-09-19 | 艾克赛特赫拉制药有限责任公司 | 治疗性化合物、组合物及其使用方法 |
| EP4070658A1 (de) * | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT76346A (en) | 1994-04-26 | 1997-08-28 | Selectide Corp | Factor xa inhibitors |
| USRE39608E1 (en) * | 1998-11-27 | 2007-05-01 | Abbott Gmbh & Co. Kg | Substituted benzimidazoles and their use as PARP inhibitors |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| DE60040676D1 (de) * | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
| JP2003509412A (ja) * | 1999-09-17 | 2003-03-11 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| ES2254385T3 (es) * | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7312043B2 (en) * | 2000-07-10 | 2007-12-25 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
| US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
| HRP20000765A2 (en) | 2000-11-10 | 2002-06-30 | Pliva D D | Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release |
| DE10065475A1 (de) * | 2000-12-28 | 2002-07-18 | Switch Biotech Ag | Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion |
| US20030114371A1 (en) * | 2001-02-07 | 2003-06-19 | Feder John N. | Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM3 |
| US7312235B2 (en) * | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| US20030211075A1 (en) * | 2001-09-27 | 2003-11-13 | Thorpe Philip E. | Combined compositions for tumor vasculature coagulation and treatment |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| FR2838057B1 (fr) * | 2002-04-05 | 2005-07-08 | Servier Lab | Nouvelle association d'un antithrombotique et d'aspirine |
| AU2003270861A1 (en) * | 2002-10-02 | 2004-04-23 | Bristol-Myers Squibb Company | Novel combination of a factor xa inhibitor and clopidogrel |
| EP1663239A4 (en) * | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
| FR2860436B1 (fr) * | 2003-10-03 | 2006-01-20 | Servier Lab | Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire |
| CN1886398A (zh) * | 2003-10-09 | 2006-12-27 | 米伦纽姆医药公司 | 作为Xa因子抑制剂的经硫醚取代的苯甲酰胺 |
| DE102004016845A1 (de) | 2004-04-07 | 2005-10-27 | Bayer Healthcare Ag | Phenylthioessigsäure-Derivate und ihre Verwendung |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| JP5020073B2 (ja) * | 2004-06-18 | 2012-09-05 | ミレニアム ファーマシューティカルズ インク． | 第Ｘａ因子阻害剤 |
| DE102004046623A1 (de) * | 2004-09-25 | 2006-03-30 | Bayer Healthcare Ag | Neue Pyrimidin-Derivate und ihre Verwendung |
| DE102005027150A1 (de) * | 2005-03-12 | 2006-09-28 | Bayer Healthcare Ag | Pyrimidincarbonsäure-Derivate und ihre Verwendung |
| JPWO2006137510A1 (ja) * | 2005-06-24 | 2009-01-22 | 小野薬品工業株式会社 | 脳血管障害時における出血低減剤 |
| RU2440986C2 (ru) * | 2005-11-08 | 2012-01-27 | Милленниум Фамэсьютикэлс, Инк. | СОЛЬ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОСТОЯЩИЕ ИЗ НАЗВАННОЙ КОМПОЗИЦИИ ТАБЛЕТКА, КАПСУЛА И ЛЕПЕШКА, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ |
| US20090186810A1 (en) | 2006-03-27 | 2009-07-23 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
| EA015942B1 (ru) | 2006-05-05 | 2011-12-30 | Милленниум Фамэсьютикэлс, Инк. | Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови |
| PT2077995E (pt) * | 2006-11-02 | 2012-05-10 | Millennium Pharm Inc | Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa |
| NZ578180A (en) * | 2006-12-08 | 2012-02-24 | Millennium Pharm Inc | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
| EP2114930A2 (en) * | 2007-01-05 | 2009-11-11 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| NZ599556A (en) * | 2007-05-02 | 2013-10-25 | Portola Pharm Inc | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
-
2008
- 2008-04-11 CN CN200880019506XA patent/CN101743001B/zh not_active Expired - Fee Related
- 2008-04-11 EP EP08742820.7A patent/EP2155195B1/en active Active
- 2008-04-11 KR KR1020097023491A patent/KR101473207B1/ko not_active Expired - Fee Related
- 2008-04-11 EA EA200970946A patent/EA020531B1/ru not_active IP Right Cessation
- 2008-04-11 AU AU2008239659A patent/AU2008239659B2/en not_active Ceased
- 2008-04-11 JP JP2010503078A patent/JP5469595B2/ja not_active Expired - Fee Related
- 2008-04-11 US US12/101,644 patent/US20080254036A1/en not_active Abandoned
- 2008-04-11 WO PCT/US2008/004760 patent/WO2008127682A2/en not_active Ceased
- 2008-04-11 BR BRPI0809655A patent/BRPI0809655B8/pt not_active IP Right Cessation
- 2008-04-11 CA CA2683793A patent/CA2683793C/en not_active Expired - Fee Related
- 2008-04-11 EP EP12196044.7A patent/EP2591783A1/en not_active Withdrawn
- 2008-04-11 NZ NZ580162A patent/NZ580162A/xx not_active IP Right Cessation
- 2008-04-11 MX MX2009010953A patent/MX2009010953A/es active IP Right Grant
- 2008-04-11 CN CN2012105706089A patent/CN103071154A/zh active Pending
-
2009
- 2009-10-07 GT GT200900260A patent/GT200900260A/es unknown
- 2009-10-09 TN TNP2009000408A patent/TN2009000408A1/fr unknown
- 2009-10-11 IL IL201433A patent/IL201433A/en active IP Right Grant
- 2009-10-12 DO DO2009000244A patent/DOP2009000244A/es unknown
-
2011
- 2011-08-19 US US13/213,912 patent/US8455440B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 US US13/889,982 patent/US20130315897A1/en not_active Abandoned
- 2013-06-18 JP JP2013127495A patent/JP2013177459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Angiolillo et al. | Basic principles of platelet biology and clinical implications | |
| CL2010000395A1 (es) | Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06) | |
| GT200800148A (es) | Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal. | |
| Ueno et al. | Role of platelets and antiplatelet therapy in cardiovascular disease | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| MX2013011721A (es) | Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| PA8759601A1 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis | |
| EA200970946A1 (ru) | Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха | |
| WO2010068866A3 (en) | Therapeutic particles suitable for parenteral administration and methods of making and using same | |
| WO2008011174A3 (en) | Jak inhibitors for treatment of myeloproliferative disorders | |
| DK1649017T3 (da) | Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer | |
| CR9427A (es) | Combinacion terapeutica en casos de hiperplasia prostatica benigna | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| IL183557A0 (en) | The use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome | |
| Song et al. | Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications | |
| UY28778A1 (es) | Derivados de pirrol como inhibidores del factor xa | |
| WO2007095389A3 (en) | Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs | |
| TN2011000228A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| CL2007000781A1 (es) | Nanoparticulas que comprenden un inhibidor de quinasa de tirosina receptora del factor de crecimiento derivado de plaquetas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades vasculares, tales como restenosis | |
| NZ598489A (en) | Combination therapy for treating proliferative diseases | |
| WO2007109459A3 (en) | Pyridines and pyridine n-oxides as modulators of thrombin | |
| NZ592615A (en) | Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 APR 2015 BY DENNEMEYER SA Effective date: 20130216 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2016 BY DENNEMEYER + CO. Effective date: 20150318 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2017 BY DENNEMEYER + CO. Effective date: 20160322 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2018 BY DENNEMEYER + CO. Effective date: 20170331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2019 BY DENNEMEYER + CO Effective date: 20180323 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2020 BY DENNEMEYER + CO. Effective date: 20190321 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 APR 2021 BY DENNEMEYER + CO Effective date: 20200401 |
|
| LAPS | Patent lapsed |